Global Electroporation Instruments and Consumables Market

Electroporation Instruments and Consumables The Global Electroporation Instruments and Consumables Market size reached USD 233.4 million in 2022 and is projected to witness lucrative growth by reaching up to USD 392.4 million by 2031. The market is exhibiting at a CAGR of 6.8% during the forecast period (2024-2031). The global electroporation instruments and consumables market is anticipated to rise throughout the forecast period due to increased product approvals and launches.

For instance, in May 2021, Lonza launched a next-generation 4D-Nucleofector Cell transfection platform. With an updated core unit and even more intuitive software, the next-generation 4D-Nucleofector Platform delivers flexibility and the same trusted performance with even greater ease of use. Additionally, in August 2021, MaxCyte signed a clinical and commercial license with Sana Biotechnology. The agreement represents MaxCyte's 14th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation technology and ExPERT platform in conjunction with the development of its hypoimmune cell therapy programs.

A high-voltage electric field is used to electroporate cells to transfer foreign genetic material, such as plasmid DNA or siRNA, into the cells. Instruments and consumables for electroporation are crucial for this procedure. Cuvettes or plates are consumables used in the electroporation process and are used to store cells and genetic material. Small, disposable cuvettes are made of plastic and have two parallel metal electrodes on each side.

The electrodes are introduced into the cuvette along with the cells and genetic material to deliver the electric pulse. Similar to cuvettes, electroporation plates are made for use with plate-based electroporation systems. The electroporation instruments and consumables industry is driven by factors such as the rising number of cancer patients, rising government and private research and development funding and technological advancements.

Market Dynamics

Rising Demand For Monoclonal Antibodies

One of the pharmaceutical industry's fastest-growing products is monoclonal antibodies. They are used in a variety of ways in the domains of biology, diagnostic imaging, medicine and biochemistry. Some of the medical applications include treating conditions including cancer, multiple sclerosis, rheumatoid arthritis, cardiovascular disorders, Crohn's disease, psoriasis and ulcerative colitis. New production technologies have been created as a result of the increase in demand for monoclonal antibodies.

Major companies have established large-scale manufacturing facilities with several cell culture bioreactors for the synthesis of antibodies. For instance, Thermo Fisher Scientific produces monoclonal antibodies, which entail stable cell lines, cell culture growth, downstream purification and product testing. The businesses use cutting-edge cell culture and electroporation equipment to create monoclonal antibodies. The market will grow as a result of the increase in demand for monoclonal antibodies.

Development of New Technological Instruments

New medical equipment that can be used to treat a variety of medical illness and diseases have been made possible by new technologies. Due to ongoing advancements in the development of novel products for transient and stable transfection with low off-target effects, numerous market participants have engaged in the production of novel methodologies, presenting prospects.

For instance, in March 2022, Thermo Fisher Scientific revealed the Gibco CTS Xenon Electroporation System, a new large-volume electroporation system that is meant to facilitate the development of cell therapies. This system allows for gene modifications without the use of conventional viral vectors. The development of new technological instruments opens up the electroporation instruments and consumables market opportunities.

Limitations of the Electroporation Method

Many cells are concurrently transfected, electroporated, or infected by a virus in the bulk processes currently utilized to introduce foreign DNA into mammalian cells. Each approach has certain drawbacks, such as limited control over DNA absorption volume, the fate and intracellular half-life of the added DNA, and the location of genomic integration.

These restrictions are a severe disadvantage when producing genetically altered stem cells for therapeutic purposes, such as gene therapy and regenerative medicine, especially when extracting sufficient numbers of these cells is challenging. However, for this vaccine modality to finally be effective in humans, DNA vaccine delivery needs to be further optimized.

Market Segment Analysis

The global electroporation instruments and consumables market is segmented based on product, application and region.

Owing to Their Characteristics and Reproducibility, the Consumables Product

The market for consumables holds 56.6% of the market share in 2022. The advanced healthcare infrastructure coupled with rapid advancements in technology is expected to play an imperative role in boosting the growth of consumables in the forecast period. Numerous things are required as consumables for conducting electroporation such as electroporation buffers, electroporation cuvettes, electroporation plates and other things.

Electroporation buffers are the consumables that usually fall into various categories of composition such as HEPES-based, phosphate-based, saline-based, cell-culture-based, Opti-MEM or Gene pulser buffer. Colored caps help detect gap width while individually wrapped cuvettes deliver precise tolerance findings with great reproducibility. The cuvettes will function with widely used electroporation systems due to standard gap size options.

Market Geographical Share

The Strong Presence of Major Players and Technological Advancements

North America holds the 39.5% market share for the electroporation instruments and consumables market in 2022. The North American region dominated the global electroporation instruments and consumables market. The rise in cancer and autoimmune diseases in North America fueled the transfection technology market.

Electroporation instruments and consumables are trending in the U.S. as the advanced healthcare infrastructure, coupled with rapid technological advancements, is expected to play an imperative role in boosting the growth of these regions’ electroporation instruments and consumables market. Moreover, biotherapeutic drugs are highly preferred for the treatment of cancer and autoimmune diseases, and an increase in the usage of these drugs is estimated to fuel the demand for transfection, as transfection is extensively employed to produce biotherapeutic drugs.

Electroporation Instruments and Consumables Companies

The major global players include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, BEX Co. Ltd, Celetrix LLC, Merck KGaA, Eppendorf AG, Harvard Bioscience Inc. (BTX), MaxCyte Inc., Lonza Group, and Mirus Bio LLC (F. Hoffmann-La Roche AG).

Russia-Ukraine Conflict Analysis

Russia and Ukraine’s war significantly Impacted the electroporation instruments and consumables market growth. Significant contributions are made by Ukraine and Russia to international cancer clinical trials. The situation in Ukraine will have a variety of effects on performing clinical trials, but it mainly affects the closure of treatment facilities, internal displacement, and forced migration.

The war is expected to affect the contribution of Russian clinical trial sites. Because resources and manpower are not allocated according to priority, cancer care in these nations has worsened. Companies like Pfizer, Bayer, Sanofi, and a few others have delayed making significant investments or developments in the country.

Key Developments
• In March 2022, Thermo Fisher Scientific introduced the new, fully customizable Gibco CTS Xenon Electroporation System, which enables large-scale cell therapy development and clinical manufacture.

The innovative electroporation technique allows for gene changes without typical viral vectors. The system's goal is to make it easier for cell therapy developers to move from clinical development to commercial manufacturing.
• In September 2022, MaxCyte, Inc. announced the signing of a strategic platform license (SPL) with Vertex Pharmaceuticals Incorporated under the terms of the agreement; Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform in the development of its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly known as CTX001™), which entitles MaxCyte to receive platform licensing fees and program related revenue.

Why Purchase the Report?
• To visualize the global electroporation instruments and consumables market segmentation based on product, application and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of electroporation instruments and consumables market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Electroporation Instruments and Consumables Market Report Would Provide Approximately 54 Tables, 46 Figures and 195 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies